Market Overview
The Global Growth Hormone Deficiency Treatment Market reached US$ 6.9 billion in 2024 and is expected to reach US$ 9.2 billion by 2032, growing at a CAGR of 12.1% during the forecast period 2025-2032.
Growth hormone deficiency (GHD) is a condition caused by the inadequate secretion of growth hormone (GH) from the anterior pituitary gland.. Growth hormone deficiency can occur due to genetic mutation and even due to the result of the pituitary gland damage.
For more details on this report – Request for Sample material
Market Dynamics: Drivers & Restraints
Increasing development of innovative solutions
The rising development of innovative solutions is expected to drive the growth hormone deficiency treatment market. The growing development of innovative solutions is a key factor driving the growth of the growth hormone deficiency (GHD) market. New, more effective treatments are improving the management of GHD, with advancements such as better delivery systems like smart pens, which increase patient convenience and adherence. Moreover, the continuous innovation in growth hormone treatments is driving new regulatory approvals and expanding treatment indications, including for pediatric and adult patients and those with conditions like adult-onset growth hormone deficiency. For instance, in April 2023, Novo Nordisk received the U.S. Food and Drug Administration (FDA) approval for a new indication for Sogroya (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg for the treatment of children aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone. With this new indication, Sogroya becomes the first and only once-weekly growth hormone (GH) treatment for children and adults.
Developing solutions with new formulations is expected to gain traction and contribute to the overall market. This expansion of treatment options broadens the patient population and contributes to the market's growth.
Complications associated with the growth hormone deficiency treatment
The complications and side effects associated with the growth hormone deficiency treatment are expected to hamper the overall market growth. This is due to the result of adverse reactions proceeding with the treatment. Common adverse effects include joint pain, muscle discomfort, and edema, which can lead to patient dissatisfaction and discontinuation of therapy. This could result in the reduced usage of the drugs and products that are being manufactured for growth hormone deficiency patients.
Market Segment Analysis
The global growth hormone deficiency treatment market is segmented based on type, treatment, route of administration, distribution channel, and region.
Type:
Pharmacological therapy segment is expected to dominate the global growth hormone deficiency treatment market share
The pharmacological therapy segment is expected to hold a major portion of the growth hormone deficiency market due to its proven effectiveness and widespread use. Recombinant growth hormone (rGH) therapies have long been the gold standard for treating GHD, providing significant benefits in terms of growth stimulation, improved bone density, and overall metabolic function.
Advances in drug formulations, such as long-acting growth hormone treatments and improved delivery systems like needle-free injectors and smart pens, have made these therapies more convenient and patient-friendly, further driving their adoption. For instance, in June 2023, Pfizer Inc. and OPKO Health Inc. received the U.S. Food and Drug Administration (FDA) approval for its NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for the treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone.
Additionally, the introduction of biosimilars, which are more affordable alternatives to branded rGH products, is expanding access to treatment and increasing market penetration. As the number of GHD diagnoses continues to rise globally, the demand for pharmacological treatments remains strong, with continuous innovation leading to new regulatory approvals and expanded indications. These factors position the pharmacological therapy segment to maintain its dominance in the market, meeting the growing demand for effective GHD management.
Market Geographical Share
North America is expected to hold a significant position in the global growth hormone deficiency treatment market share
North America is expected to hold a dominant position in the global growth hormone deficiency market due to several significant factors. The region benefits from high awareness of GHD, advanced diagnostic technologies, and well-established healthcare infrastructure, which leads to early diagnosis and prompt treatment. North American patients have greater access to cutting-edge growth hormone therapies, such as recombinant growth hormone and long-acting formulations, ensuring effective treatment options.
Additionally, the presence of leading pharmaceutical companies and research institutions in the U.S. drives innovation and continuous development of new treatment options. Thus, the above factors position North America to maintain a dominant share of the global GHD treatment market.
Competitive Landscape
The major global players in the growth hormone deficiency treatment market include Pfizer Inc., Sandoz AG, Novo Nordisk Inc., Eli Lilly and Company, Ferring, Genentech, Inc., Merck KGaA (EMD Serono, Inc.), Reliance Life Sciences, AnkeBio Co., Ltd and Omicron Pharma among others.
| Metrics | Details | |
| CAGR | 12.1% | |
| Market Size Available for Years | 2022-2032 | |
| Estimation Forecast Period | 2024-2032 | |
| Revenue Units | Value (US$ Bn) | |
| Segments Covered | Type | Pediatric, Adult |
| Treatment | Pharmacological Therapy, Recombinant Human Growth Hormone Therapy, Human Pituitary Gland Extracts, Others | |
| Route of Administration | Intravenous, Intramuscular, Others | |
| Distribution Channel | Hospital Pharmacy, Online Pharmacy, Retail Pharmacy | |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa | |
Key Developments
- In December 2023, Ascendis Pharma A/S announced positive topline results from foresiGHt, its Phase 3 randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled (open-label) trial to compare the efficacy and safety of TransCon hGH (lonapegsomatropin) with placebo and daily hGH (human growth hormone, somatropin) in adults with growth hormone deficiency (GHD).
Why Purchase the Report?
- Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The Global Growth Hormone Deficiency Treatment Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2023
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
